V
Vanina Rodriguez
Researcher at University of Barcelona
Publications - 34
Citations - 815
Vanina Rodriguez is an academic researcher from University of Barcelona. The author has contributed to research in topics: Mantle cell lymphoma & BET inhibitor. The author has an hindex of 15, co-authored 34 publications receiving 675 citations. Previous affiliations of Vanina Rodriguez include University of Buenos Aires & National Scientific and Technical Research Council.
Papers
More filters
Journal ArticleDOI
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
Alexandra Moros,Vanina Rodriguez,Ifigènia Saborit-Villarroya,Arnau Montraveta,Patricia Balsas,P Sandy,A. Martinez,Adrian Wiestner,Emmanuel Normant,Elias Campo,Patricia Pérez-Galán,Dolors Colomer,Gaël Roué +12 more
TL;DR: It is suggested that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in Mcl cases refractory to proteasome inhibition.
Journal ArticleDOI
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
Maria Castella,Anna Boronat,Raquel Martín-Ibáñez,Vanina Rodriguez,Guillermo Suñe,Miguel Caballero,Berta Marzal,Lorena Perez-Amill,Beatriz Martín-Antonio,Julio Castaño,Clara Bueno,Olga Balagué,Europa Azucena González-Navarro,Carles Serra-Pagès,Pablo Engel,Ramon Vilella,Daniel Benitez-Ribas,Valentín Ortiz-Maldonado,Joan Cid,Jaime Tabera,Josep M. Canals,Miquel Lozano,Tycho Baumann,Anna Vilarrodona,Esteve Trias,Elias Campo,Pablo Menendez,Pablo Menendez,Alvaro Urbano-Ispizua,Jordi Yagüe,Patricia Pérez-Galán,Susana Rives,Julio Delgado,Manel Juan +33 more
TL;DR: It is shown that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation.
Journal ArticleDOI
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Anna Esteve-Arenys,Juan G. Valero,Aranzazu Chamorro-Jorganes,D. Gonzalez,Vanina Rodriguez,Ivan Dlouhy,Itziar Salaverria,Elias Campo,Dolors Colomer,A. Martinez,Grzegorz Rymkiewicz,Patricia Pérez-Galán,Armando López-Guillermo,Gaël Roué +13 more
TL;DR: It is demonstrated that single-agent ABT-199 efficiently displaces BAX from BCL-2 complexes but fails to maintain a significant antitumor activity over time in most MYC+/BCL2+DHL cell lines and primary cultures, as well as in a xenograft mouse model of the disease.
Journal ArticleDOI
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Silvia Xargay-Torrent,Mónica López-Guerra,Laia Rosich,Arnau Montraveta,Jocabed Roldán,Vanina Rodriguez,Neus Villamor,Marta Aymerich,Chandraiah Lagisetti,Thomas R. Webb,Carlos López-Otín,Elias Campo,Dolors Colomer +12 more
TL;DR: First evidence that the spliceosome is a relevant therapeutic target in CLL is provided, supporting the use of splicing modulators alone or in combination with ibrutinib as a promising approach for the treatment of CLL patients.
Journal ArticleDOI
Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism.
E P Bello,R Casas-Cordero,Gregorio L. Galiñanes,Eric Casey,Mariano A. Belluscio,Vanina Rodriguez,Daniela Noain,Mario Gustavo Murer,M Rubinstein,M Rubinstein +9 more
TL;DR: It is found that loss of D2R during adulthood causes severe motor impairments, including hypolocomotion, deficits in motor coordination, impaired learning of new motor routines and spontaneous catatonia.